Zydus Lifesciences consolidated net profit rises 24.48 percent YoY to Rs 622.9 crore in Q3
Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal.
Ahmedabad: Zydus Lifesciences Ltd on Friday reported a 24.48 percent rise in consolidated net profit at Rs 622.9 crore for the third quarter ended December 31, 2022.
The company had posted a consolidated net profit of Rs 500.4 crore in the same period last fiscal, Zydus Lifesciences Ltd said in a regulatory filing.
Consolidated total revenue from operations during the quarter under review stood at Rs 4,362.3 crore, as against Rs 3,639.8 crore in the year-ago period, it added.
Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal.
In the third quarter, its business in India comprising formulations as well as consumer wellness registered revenues of Rs 1,643.6 crore, up 13 per cent, while the US formulations business registered revenues of Rs 1,925 crore, up 29 percent from the year-ago period, the company said.
Emerging markets formulations business registered revenues of Rs 307.8 crore, up 15 percent and Europe formulations business clocked revenues of Rs 70.5 crore, a growth of 4 percent.
Zydus Lifesciences Managing Director, Sharvil Patel said, “With India formulations in a double-digit growth trajectory and US business continuing to build traction, portfolio execution will sustain growth momentum.”
Zydus group is headquartered in Ahmedabad, India. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.
Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain), and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
The group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products, and wellness products.
